$BMRN Recent News Biotech comeback stalls as Wall

New Post Public Reply Private Reply Replies (0) Message Board

Jun 21, 2014 at 7:21 AM

$BMRN Recent News

Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt
Major U.S. benchmarks pull in to first support 12:27 p.m. March 10, 2014 - Michael Ashbaugh
BioMarin shares rally as FDA mutes criticism of rare disorder drug 6:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 12:10 p.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 6:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 11:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 1:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 3:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 5:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 12:56 p.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 1:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 12:39 p.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 1:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 12:17 p.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 12:49 p.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 7:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 10:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 10:46 a.m. Oct. 3, 2012 - Michael Ashbaugh

Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate 2:19 p.m. June 20, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – SHPG CBST BMRN SLXP 7:45 a.m. June 20, 2014 - InvestorPlace.com
The Trader Daily 7:30 a.m. June 19, 2014 - RealMoney.com
Amicus Therapeutics Still A "Show Me" Story 2:11 p.m. June 12, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More 7:58 a.m. June 12, 2014 - 247WallSt.com
How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today? 7:53 a.m. June 12, 2014 - TheStreet.com
The Trader Daily 7:30 a.m. June 12, 2014 - RealMoney.com
7 Biotechnology Stocks to Buy Now 5:45 a.m. June 11, 2014 - InvestorPlace.com
UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical 8:41 a.m. June 9, 2014 - benzinga.com
How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today? 7:54 a.m. June 9, 2014 - TheStreet.com
Benzinga's Top Upgrades 6:52 a.m. June 9, 2014 - benzinga.com
The Trader Daily 7:30 a.m. June 5, 2014 - RealMoney.com
Insider Trading Alert - TWO, CCL And BMRN Traded By Insiders 10:30 a.m. June 4, 2014 - TheStreet.com
Drugs Stocks On The Rise With Help From 3 Stocks 1:02 p.m. June 3, 2014 - TheStreet.com
BioMarin's Pipeline Advances - Analyst Blog 11:40 a.m. May 29, 2014 - Zacks.com
The Trader Daily 7:30 a.m. May 29, 2014 - RealMoney.com
A Tale of Diversification 2:00 p.m. May 19, 2014 - RealMoney.com
Top Biotech Stocks for Cancer Cures from Cowen 8:08 a.m. May 16, 2014 - 247WallSt.com
Insider Trading Alert - WMGI, MSM And BMRN Traded By Insiders 10:30 a.m. May 14, 2014 - TheStreet.com
'Mad Money' Lightning Round: BioMarin Is for Real 6:00 a.m. May 8, 2014 - TheStreet.com

Relypsa Adds Industry Veterans Daniel K. Spiegelman and kenneth J. Hillan to Its Board of Directors 4:06 p.m. June 19, 2014 - GlobeNewswire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease 8:02 a.m. May 27, 2014 - GlobeNewswire
Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex 8:29 a.m. May 7, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma 9:15 a.m. May 6, 2014 - PR Newswire - PRF
BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th 8:02 a.m. May 6, 2014 - GlobeNewswire
BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress 4:06 p.m. May 1, 2014 - GlobeNewswire
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages 11:08 a.m. April 28, 2014 - GlobeNewswire
Earnings Schedules, Acquisition Agreements, and Financial Results Release - Analyst Notes on Mallinckrodt, BioMarin, Salix Pharmaceuticals, St. Jude Medical and Quest Diagnostics 8:00 a.m. April 25, 2014 - PR Newswire - PRF
BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET 8:02 a.m. April 16, 2014 - GlobeNewswire
Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma 11:15 a.m. April 15, 2014 - PR Newswire - PRF
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver 9:31 a.m. April 14, 2014 - PR Newswire - PRF
FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets 8:02 a.m. April 14, 2014 - GlobeNewswire
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin 8:00 a.m. April 11, 2014 - PR Newswire - PRF
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma 11:55 a.m. March 26, 2014 - PR Newswire - PRF
BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors 8:01 a.m. March 21, 2014 - GlobeNewswire
Critical Alerts For Voxeljet, QUALCOMM, Canadian Solar, NQ Mobile, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. March 19, 2014 - PR Newswire - PRF
Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update 8:16 a.m. March 19, 2014 - GlobeNewswire
BioMarin Announces Pricing of Public Offering of Common Stock 9:00 a.m. March 5, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

SMPL Faces Legal Drama: What Investors Need to Know

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...